The results of the study of three-negative breast cancer 3 were published on the first line of the Mercadon K drug treatment

On May 26, Mersadon (MSD) announced that it will present the results of Phase 3 clinical trial KEYNOTE-355 orally at the 2020 American Society of Clinical Oncology (ASCO) online academic conferenceThe trial was designed to assess the effectiveness and safety of PD-1 mono-pembolizumab (commonly known as "K-drug") in combination with chemotherapy for metastatic triple-negative breast cancer patientsThe results show that Paboli zumaty combined chemotherapy can significantly improve the patient's progressionless survivalThis result may have the potential to change treatment options for patients with specific metastatic triple negative breast cancertriple-negative breast cancer is the most "toxic" and most difficult type of breast cancer, its estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are negative, accounting for 15% of all breast cancer pathological typesAt present, the treatment options for patients with triple-negative breast cancer are very limited, the prognosis is usually very poor, and patients urgently need new treatment optionsKEYNOTE-355 is a randomized, double-blind, phase 3 clinical study designed to compare the effects of Paboli-zumam with placebo-combined chemotherapy in untreated, non-surgical, or metastatic triple-negative breast cancerThe main endpoints of the experiment were Progressless Life (PFS) and Total Lifetime (OS)The median follow-up time in the Pablo Zuma-mono-combined chemotherapy group was 17.5 months and the median follow-up time in the chemotherapy group was 15.5 months, as of December 11, 2019, according to data released by Mercadon in the 2020 ASCO SummaryThe results showed that the progressionless life of the patient was significantly prolonged by papolizumab-combination chemotherapy:in patients with PD-L1 expression index (CPS) and 10 patients, the median PFS was 9.7 months in the PapoliZumad-chemotherapy group, compared to 5.6 months in the chemotherapy group;the Paboli-Zuma-and-chemotherapy group had good tolerance and no new safety problems were foundthis study will continue to assess the patient's overall lifetime indicators"No progression-like survival results from the KEYNOTE-355 trial have the potential to change treatment options for patients with specific metastatic triple-negative breast cancer," said DrRoy Baynes, Senior Vice President of Global Clinical Research and Chief Medical Officer,Mercado Laboratory References the results of the study of patients with specific metastatic triple-negative breast cancer treated with the combination of monpatonic paboli monoantigen smh.com.au Retrieved May 26, 2020, from https:// 2020 ASCO Meeting Summary From https://meetings.asco.org/